Yuhao Dong | Immunology and Microbiology | Best Scholar Award

Best Scholar Award

Yuhao Dong
Nanjing Agricultural University, China

                    Yuhao Dong
Affiliation Nanjing Agricultural University
Country China
Scopus ID 56707567500
Documents 41
Citations 796
h-index 14
Subject Area Immunology and Microbiology
Event Global Innovation Technologist Awards

Yuhao Dong is a researcher affiliated with Nanjing Agricultural University, China, whose listed scholarly output includes studies on bacterial virulence, antimicrobial resistance, and microbial systems. His two supplied publications address CRISPR-dependent gene regulation in piscine Streptococcus agalactiae and the TonB system associated with macrolide resistance in Aeromonas hydrophila. These studies provide a basis for describing his research interests in microbial pathogenesis and bacterial resistance mechanisms. The bibliometric figures presented here are supplied profile data and should be checked against the current Scopus record before publication. [1] [2]

Abstract

This article presents a research profile of Yuhao Dong in relation to the Best Scholar Award. The supplied record lists 41 documents, 796 citations, and an h-index of 14. His two identified publications investigate bacterial gene regulation, virulence, and antimicrobial resistance. These topics are relevant to microbiology and infectious disease research. The profile summarizes the available information without treating bibliometric indicators alone as proof of research quality or independently verified award selection.

Keywords

Yuhao Dong; Best Scholar Award; microbiology; bacterial virulence; CRISPR-dependent gene regulation; antimicrobial resistance; Streptococcus agalactiae; Aeromonas hydrophila; research impact.

Introduction

Understanding bacterial pathogenesis and resistance is important for infectious disease research, animal health, and the study of microbial adaptation. Investigations into gene-regulatory systems can help clarify how bacteria maintain virulence, while research on efflux pumps and associated transport systems can inform the study of antimicrobial resistance. Dong’s supplied publications address these complementary questions through studies of bacterial species relevant to piscine and veterinary microbiology. [1] [2]

Research Profile

The supplied profile associates Dong with Nanjing Agricultural University in China and identifies Immunology and Microbiology as the subject area. His listed bibliometric indicators—41 documents, 796 citations, and an h-index of 14—offer quantitative measures of recorded publication and citation activity. Their interpretation depends on database coverage, profile accuracy, publication dates, and citation practices within the relevant discipline. [3]

Research Contributions

The 2021 study on piscine Streptococcus agalactiae examines CRISPR-dependent endogenous gene regulation in relation to bacterial virulence. The second study investigates the TonB system in Aeromonas hydrophila NJ-35 and its role in MacA2B2 efflux pump-mediated macrolide resistance. Together, these publications indicate research engagement with molecular mechanisms underlying bacterial pathogenicity and drug resistance. Specific experimental findings should be interpreted in the context of each full paper. [1] [2]

Publications

  1. Dong, Y. et al. (2021). “CRISPR-dependent endogenous gene regulation is required for virulence in piscine Streptococcus agalactiae.” Emerging Microbes & Infections, 10(1), 2113–2124. [1]
  2. Dong, Y. et al. (2021). “The TonB system in Aeromonas hydrophila NJ-35 is essential for MacA2B2 efflux pump-mediated macrolide resistance.” Veterinary Research, 52(1), article 63. [2]

These entries are based on the bibliographic details supplied for this article. DOI identifiers have not been independently established here and are therefore not inferred.

Research Impact

The supplied citation count and h-index suggest that Dong’s publications have received measurable scholarly attention. Citation indicators, however, vary with time and database coverage and do not independently establish the originality, reproducibility, or practical significance of individual findings. A fuller assessment would consider publication quality, methodological rigor, research contributions, collaboration, and the influence of the work on subsequent studies.

Award Suitability

The Best Scholar Award profile can present Dong’s documented research topics, publication record, and bibliometric indicators as information relevant to scholarly recognition. A fair assessment by the Global Innovation Technologist Awards should additionally verify the researcher’s identity, institutional affiliation, publication records, and eligibility against the award’s published criteria. This profile does not assert that an award has been formally granted.

Conclusion

Yuhao Dong’s supplied publication record highlights research into bacterial virulence and antimicrobial resistance. His reported bibliometric indicators provide context for reviewing his scholarly activity, while the two identified papers offer specific examples of his research interests. Verification of the underlying records and assessment of the scientific contributions remain important steps in preparing a complete award profile.

References

    1. Dong, Y. et al. (2021). “CRISPR-dependent endogenous gene regulation is required for virulence in piscine Streptococcus agalactiae.” Emerging Microbes & Infections, 10(1), 2113–2124. Bibliographic details supplied for this profile.
    2. Dong, Y. et al. (2021). “The TonB system in Aeromonas hydrophila NJ-35 is essential for MacA2B2 efflux pump-mediated macrolide resistance.” Veterinary Research, 52(1), article 63. Bibliographic details supplied for this profile.
    3. Elsevier. (n.d.). Scopus author details: Yuhao Dong, Author ID 56707567500. Scopus. Bibliometric figures in this article are based on the supplied profile data and should be confirmed against the current record.
      https://www.scopus.com/authid/detail.uri?authorId=56707567500
    4. Global Innovation Technologist Awards. (n.d.). Official award website. Award information and eligibility criteria should be verified on the official website.
      innovationtechnologist.com

Amr Radwan | Immunology | Best Researcher Award

Dr. Amr Radwan | Immunology | Best Researcher Award

Executive Medical Director at Regeneron, United Kingdom

Dr. Amr AH Radwan is a distinguished medical affairs leader with over two decades of global experience spanning clinical medicine, pharmaceutical medicine, immunology, gastroenterology, and strategic leadership in drug development and market access. Currently serving as Executive Medical Director at Regeneron Pharmaceuticals Inc., he brings deep scientific expertise and cross-functional insight to global medical affairs, particularly in immunological disorders and biologics. His work bridges the interface of clinical innovation, medical strategy, regulatory frameworks, and international healthcare markets.

Publication Profile 

Orcid

Educational Background 🎓

  • University of Cambridge

    • MB BChir (Bachelor of Medicine and Surgery), 1998

    • BA in Pathology (Honours), 1996

    • MA (Cantab), 1999

  • Royal College of Surgeons (Edinburgh)

    • AFRCS Part 1 (MCQ I & II), 2001

  • The Berne Institute, Kegworth

    • Foundation Training in Transactional Analysis Counselling & Psychotherapy, 2003

  • University of Cardiff

    • Diploma in Pharmaceutical Medicine, 2010

  • Royal College of Physicians

    • Membership of Faculty of Pharmaceutical Medicine, 2011

    • Specialist Training in Pharmaceutical Medicine, 2011

    • Fellowship, 2016

Professional Experience 💼

🏢 Regeneron Pharmaceuticals Inc. (2018–Present)

  • Executive Medical Director, Global Medical Affairs (2022–Present)

  • Senior Director, Global Medical Affairs (2019–2021)

  • Senior Director, Medical Affairs EU (2018–2019)

    • Key leadership in global immunology franchise across dermatology, respiratory, and GI indications (e.g., Dupilumab, Itepekimab).

    • Led GI franchise (EoE, EoG, eUC) strategy and ex-US medical organization restructuring.

    • Partnered with commercial, legal, and R&D teams for European, Canadian, and Japanese market expansions.

🏢 Aimmune Therapeutics Ltd. (2016–2018)

  • Vice President, Medical Affairs & Market Access

    • EU and global leadership for peanut allergy therapy; directed Drug Safety & PV, Market Access, and clinical trial governance.

🏢 Norgine Pharmaceuticals UK Ltd. (2014–2016)

  • Medical Director – EU

    • Led EU medical affairs, market access, PV, and NICE submission strategies; managed 8 country-level medical teams; oversaw clinical trials and licensing responses.

Research Interests 🔬

  • Pharmaceutical Medicine & Clinical Drug Development

  • Immunology, Dermatology, and Gastroenterology (e.g., EoE, PN, CRSwNP)

  • Allergic Disorders and Biologics (e.g., anti-IL33, anti-Fel D1)

  • Regulatory Compliance, Pharmacovigilance & Risk Management

  • Clinical Strategy and Market Access Studies

Awards and Honors🏆✨

  • Queens’ College Exhibition Prize (1994–1996)
    Awarded for First Class academic performance in Preclinical Sciences.

  • Fawcett Memorial Prize (1998)
    Recognized for Outstanding Communication Skills.

  • Fellowship of the Faculty of Pharmaceutical Medicine (2016)
    Awarded by Royal College of Physicians for significant contributions to Pharmaceutical Medicine.

Additional Credentials & Interests

  • Languages & Communication: Fluent in Arabic, English, and French.

  • Advanced Certifications:

    • IAM-trained motorcyclist (Institute of Advanced Motorists)

    • PADI Advanced & BSAC Sports Scuba Diving certifications

  • Hobbies:

    • Partner dancing (Argentine Tango, Blues, Modern Jive)

    • Literature, philosophy, and motorcycling

Conclusion🌟

Dr. Amr AH Radwan is a highly accomplished physician-leader whose contributions have shaped global medical affairs practices, especially in immunology and allergy-based therapeutics. His unique blend of clinical training, regulatory expertise, and cross-continental leadership makes him a significant figure in modern pharmaceutical medicine and translational healthcare strategy. He is well-suited for high-level recognition, awards, and continued leadership in both academic and industry circles.

Publications 📚

  1. 📄 A Real-World Study of Cumulative Steroid Burden Among Patients with Eosinophilic Esophagitis in the United States
    📰 Clinical Gastroenterology and Hepatology (Mar 2025)
    🔗 DOI: 10.1016/j.cgh.2025.01.010


  1. 📄 Baseline Disease Characteristics by Surgery History Among Patients with CRSwNP: AROMA Registry
    📰 American Journal of Otolaryngology (Mar 2025)
    🔗 DOI: 10.1016/j.amjoto.2024.104596


  1. 📄 Dupilumab Efficacy and Safety in Children With Moderate to Severe Asthma and High Blood Eosinophils: VOYAGE (Post Hoc)
    📰 The Journal of Allergy and Clinical Immunology: In Practice (Mar 2025)
    🔗 DOI: 10.1016/j.jaip.2024.11.014


  1. 📄 Burden of Eosinophilic Esophagitis in Adults and Adolescents: Real-World Analysis
    📰 Diseases of the Esophagus (Mar 3, 2025)
    🔗 DOI: 10.1093/dote/doaf024


  1. 📄 Dupilumab Efficacy in EoE Irrespective of Prior Swallowed Corticosteroids: LIBERTY EoE TREET Trial
    📰 Expert Review of Gastroenterology & Hepatology (Feb 2025)
    🔗 DOI: 10.1080/17474124.2025.2461516


  1. 📄 Current Smoker: A Clinical COPD Phenotype Affecting Disease Progression and Therapy Response
    📰 American Journal of Respiratory and Critical Care Medicine (Feb 12, 2025)
    🔗 DOI: 10.1164/rccm.202407-1379ci


  1. 📄 Dupilumab Induces Long-Term On-Treatment Clinical Remission in Type 2 Asthma
    📰 The Journal of Allergy and Clinical Immunology: In Practice (Jan 2025)
    🔗 DOI: 10.1016/j.jaip.2024.10.009


  1. 📄 Disease Burden and Symptoms Impacting Quality of Life in Pediatric EoE Patients
    📰 Gastro Hep Advances (2024)
    🔗 DOI: 10.1016/j.gastha.2024.08.009


  1. 📄 Real-World Characteristics of Severe Asthma Patients Before Dupilumab: ProVENT Study
    📰 Respiration (2024)
    🔗 DOI: 10.1159/000535390


  1. 📄 Dupilumab Efficacy in Children With Type 2 Asthma on High-/Medium-Dose ICS (VOYAGE)
    📰 The Journal of Allergy and Clinical Immunology: In Practice (Dec 2024)
    🔗 DOI: 10.1016/j.jaip.2024.08.038